Literature DB >> 6751738

Basal C-peptide in the discrimination of type I from type II diabetes.

P G Webb, A M Bonser.   

Abstract

Basal serum C-peptide concentrations in diabetic patients showed two groups. Diabetic patients with low C-peptide levels (less than or equal to 0.16 nmol/L) have clinical characteristics of type I diabetes, and all were on insulin therapy. With long duration of diabetes, an increasing proportion had undetectable C-peptide. Diabetic patients with high C-peptide levels (greater than 0.16 nmol/L) resemble type II diabetes. In this group 30% were on insulin therapy but duration of known disease was not associated with any decline in the high basal C-peptide levels. The small proportion of diabetic patients with basal serum C-peptide in the range of 0.17-0.32 nmol/L have indeterminate status.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6751738     DOI: 10.2337/diacare.4.6.616

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  14 in total

1.  A simple clinical approach to discriminate between "true" and "pseudo" secondary failure to oral hypoglycaemic agents.

Authors:  L Scionti; P Misericordia; A Santucci; F Santeusanio; P Brunetti
Journal:  Acta Diabetol       Date:  1992       Impact factor: 4.280

Review 2.  The expanding clinical use of C-peptide radioimmunoassay.

Authors:  M Rendell
Journal:  Acta Diabetol Lat       Date:  1983 Apr-Jun

3.  C-peptide measurement in the differentiation of type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  H L Katzeff; P J Savage; B Barclay-White; M Nagulesparan; P H Bennett
Journal:  Diabetologia       Date:  1985-05       Impact factor: 10.122

4.  The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin?

Authors:  I Peacock; R B Tattersall
Journal:  Br Med J (Clin Res Ed)       Date:  1984-06-30

5.  Evaluation of beta-cell function in diabetic Taiwanese children using a 6-min glucagon test.

Authors:  Yi-Ching Tung; Jing-Sheng Lee; Wen-Yu Tsai; Pei-Hung Hsiao
Journal:  Eur J Pediatr       Date:  2007-09-15       Impact factor: 3.183

6.  Serum C-peptide levels and risk of death among adults without diabetes mellitus.

Authors:  Jin-young Min; Kyoung-bok Min
Journal:  CMAJ       Date:  2013-04-15       Impact factor: 8.262

7.  Therapeutic effects of soluble dietary fiber consumption on type 2 diabetes mellitus.

Authors:  Chunye Chen; Yuan Zeng; Jing Xu; Hongting Zheng; Jun Liu; Rong Fan; Wenyi Zhu; Lijia Yuan; Yu Qin; Shihui Chen; Yong Zhou; Ying Wu; Jing Wan; Mantian Mi; Jian Wang
Journal:  Exp Ther Med       Date:  2016-05-20       Impact factor: 2.447

8.  Pharmacokinetics of caffeine in patients with decompensated type I and type II diabetes mellitus.

Authors:  T Zysset; H Wietholtz
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Misunderstanding in the classification of diabetes mellitus. What's in a name?

Authors:  M L Elks; J W Sawyer
Journal:  West J Med       Date:  1993-07

10.  Discrimination of type I from insulin-treated type II diabetic patients by C-peptide measurement.

Authors:  P Cravarezza; E Radaeli; C Toffoli; C Rigosa
Journal:  Acta Diabetol Lat       Date:  1986 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.